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1. Introduction
   The new fatal diseases are being continuously reported in the 
past decade[1]. Ebola virus diseases (EVDs) have always been a 
challenge and a global menace since its discovery in 1976 by Dr. 
Peter Piotin in Zaire, Africa (now Democratic Republic of Congo) 
from the blood of a catholic nun who suspected of having yellow 
fever[2]. Ebola haemorrhagic fever (EHF) is a zoonotic disease 
transmitted accidentally by direct contact with infected live or 
dead animals. EHF is an acute viral syndrome with fever and 
subsequent bleeding diathesis marked by high mortality in human 
and nonhuman primates (monkeys, gorillas and chimpanzees). 
Ebola virus is a violent pathogen, a lipid-enveloped negatively 
stranded RNA virus that belongs to the viral family Filoviridae[3]. 
Exhaustive investigation on EHF in the equatorial region of the 
Democratic Republic of Congo between 1981 and 1985 pointed out 
that EHF episodically come out from nature to infected humans[4]. 
EHF is caused by any of five genetically different members of the 
Filoviridae family: Zaire ebolavirus (ZEBOV), Sudan ebolavirus 
(SEBOV), Côte d’Ivoire ebolavirus, Bundibugyo ebolavirus (BDBV) 
and Reston ebolavirus (REBOV). Côte d’Ivoire ebolavirus has 
been accompanied with only one human case[5]. REBOV has only 
caused disease in non-human primates (NHP) and was found in 
swine suffering from porcine reproductive and respiratory disease 
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syndrome[6]. Zaire, Sudan and Bundibugyo Ebola viruses are 
accountable for most of the EHF epidemic but ZEBOV establish a 
particularly serious threat to both human and NHPs in sub-Saharan 
Africa. EHF has been associated with large human outbreaks, with 
case fatality rates for ZEBOV as high as 90%[7-9]. The 2014 West 
Africa ebola outbreak is an ongoing epidemic of the EVD in West 
Africa. The outbreak began in the republic of Guinea in February 
of 2014. Since its initial outbreaks, the virus has already spread to 
the republic of Liberia and the Sierra Leone. The 2014 West Africa 
Ebola outbreak is believed to be the most terrible in medical history 
with regards to both the number of human cases and fatalities[10-13]. 
Presently, there are no approved antiviral drugs or vaccines against 
filoviruses. The prevention of EHF requires more awareness of the 
pathology of the ailment, especially the role of wildlife, especially 
bats, in the spread of Ebola virus to humans. The present review is 
an attempt to summarize various essential aspects of EVD or EHF.
2. Virology
   The EVD, previously known as EHF is a severe condition caused by 
a virus belonging to genus Ebolavirus, family Filoviridae and order 
Mononegavirales. The family Filoviridae comprises of one genus, 
Filovirus, which contains two species, morphologically identical 
but serologically distinct: Marburg virus and Ebola virus. There 
are five Ebola subtypes BDBV, ZEBOV, REBOV, SEBOV and Taï 
Forest ebolavirus (TAFV) which vary in pathogenicity, antigenicity 
and genomic constitution[16]. BDBV, ZEBOV and SEBOV have 
been accompanied with large EVD epidemic near the tropical rain 
forests of Central and West African distant villages; among these 
three ZEBOV are responsible for high mortality rates in humans. 
REBOV and TAFV were not accustomed for illness or mortality in 
human. The gene products of ebola and Marburg viruses exhibit a 
noteworthy degree of similarity and in some areas extensive identity, 
but are encoded in contradictory nucleotide sequences[17,18](Figure 
1).
Polymerase complex protein (VP35)
Minor nucleoprotein (VP30)
GP
VP24 Matrix (VP40)
Polymerase (L) Genomic RNA
Figure 1. Schematic representation of the ebola virus[14,15,33].
VP: virion protein; GP: glycoprotein.
3. Ecology
   Tropical rain forests in Africa provide a general ecosystem for 
ebola virus emergence, presenting a rich animal biodiversity and 
outbreak appears to be periodical. EVD is a conventional zoonotic 
disease. The evidences indicate that fruit bats are the reservoir 
for both ebola and Marburg virus. The first indication for the 
manifestation of Zaire ebola virus in naturally infected fruit bats was 
recorded by recognition of viral RNA and antibodies in three tree-
roosting species: Hypsignathus monstrosus, Epomops franqueti, 
Myonycteris torquata and therefore have been associated as the 
potential fall over source for ebola virus[17]. Zaire ebola virus 
has not been well isolated from naturally infected animals. The 
identification and successful isolation of Marburg virus from the 
cave-dwelling fruit bat Rousettus aegyptiacus provide support to 
the idea that bats are a reservoir species for filoviruses[19]. Ebola 
virus might endure as an asymptomatic or subclinical infection in 
the reservoir species, with little or no transmission and might be 
intermittently provoked through a suitable stimulus. The stimulus 
might be stress, co-infection and change in food sources and 
pregnancy as displayed in vivo and in vitro investigations[20,21]. 
This hypothesis describes the infrequent nature and periodicity of 
EHF in Africa. Mammalian species including NHP vulnerable to 
infection are considered as the dead end hosts. The probabilities of 
seasonal outcome on introduction of ebola virus infection have also 
been proposed[22,23]. The future studies require consideration of the 
level of infections of ebola viruses in fruit or insectivorous bats in 
areas prevalent for these viruses. Issues such as virus pathology and 
perseverance in bats, conceivable activation process of insistent virus 
and possible transmission routes required to be monitored by field 
and experimental investigations. Other possible reservoir species and 
a role for potential augmenting hosts, particularly after the detection 
of Reston ebola virus in pigs in the Philippines should also be 
investigated[24].
4. Epidemiology
   The first instance of filovirus haemorrhagic fever was reported in 
1967 in Germany and the former Yugoslavia and the contributing 
agent was recognized as Marburg virus[25]. In 1976, epidemic of 
haemorrhagic fever was reported in two adjacent areas: first in 
Southern Sudan and consequently in Northern Zaire. The outbreak 
commenced with malaria like symptoms and transmitted due to 
application of unsterilized needles in the clinics. An uncertain 
causative agent was quarantined from patients in both epidemics 
and named ebola virus after a small ebola river in northwestern 
Democratic Republic of the Congo. These two outbreaks were 
caused by two distinct species of ebola virus, Sudan ebola virus 
(SEBOV) and Zaire ebola virus (ZEBOV)[26-28]. The third African 
ebola virus species, Tai forest ebola virus (earlier known as Ivory 
Coast or Cote dÊIvoire) was reported in 1994. The virus was isolated 
from a diseased ethnologist who had worked in the Tai forest reserve 
in Cote dÊIvoire and had performed a necropsy on a chimpanzee that 
had resided with a crowd where numerous members had expired 
due to EHF[29]. The recent breakthrough is the Bundibugyo ebola 
virus, existing in equatorial region of Africa[9]. Another ebola virus 
species, Reston ebola virus (discovered in Reston, Virginia, USA, 
in November 1989) has been recognized as non-pathogenic for 
humans[30]. Numerous outbreaks due to several species of ebola 
virus have been reported in diverse parts of Africa. Historically, 
EVD has occurred in areas around the rain forests of Central Africa. 
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Conversely, recent epidemics are now basically in distant villages 
of Central and Western Africa. The transmission of EVD to adjacent 
region is a crucial alarm. In July 2014, World Health Organization 
(WHO) delegates organized a crisis summit in Ghana to harmonize 
a more competent response to the ebola epidemic in West Africa. 
The Centers for Disease Control (CDC), WHO, the American Nurses 
Association, and many other national or international associations 
have supplied the most recent knowledge about EVD to clinicians, 
students, and travelers. EVD outbreaks have a fatality rate of 60% to 
90%, depending upon time of diagnosis, accessibility of sympathetic 
medication, and EVD subtype[31].
5. Pathophysiology
   A virus is an infectious, intracellular parasite. The genetic 
constitution of a virus is either DNA or RNA. A filovirus is a 
filamentous, enveloped particle with single stranded, non-segmented 
RNA molecule with diameter of 80 nm and varying length, which 
may be up to 1 400 nm, emerged as bacilliform particles that 
encode seven genes: nucleoprotein, VP35, VP40, GP, VP30, VP24, 
RNA-dependent RNA polymerase (L). The genomes of the five 
distinct ebolaviruses (BDBV, ZEBOV, REBOV, SEBOV and TAFV) 
vary in sequence and the number and location of gene overlaps. 
Amongst these, nucleoprotein, VP35, VP30 and RNA-dependent RNA 
polymerase are associated with viral replication and transactivation. 
VP40 is the matrix protein and involves in budding and delivery 
of viral particle, although VP24 is the minor matrix protein and 
accompanied with nucleocapsid formation. Both the matrix proteins, 
VP40 and VP24 are identified to obstruct interferon signaling. The 
only surface protein controlled by the filovirus is the GP, present 
as trimeric spikes comprising of GP1 and GP2. The non-structural 
soluble form of GP, sGP, a unique product of ZEBOV GP gene, gets 
secreted from infected cells[32]. EVD adhere to 6 phases of viral 
replication: attachment, penetration, uncoating, replication and 
expression, maturation and release/delivery of virus.
6. Pathogenesis and transmission
   The wild animals like primates (chimpanzees, gorillas, baboons, 
duikers and African green monkeys) and fruit bats (Hypsignathus 
monstrosus, Epomops franqueti, Myonycteris torquata and 
Pteropodidae) are the natural hosts for the EVD and are responsible 
for transmission of ebola virus from animals to humans[34]. The 
animal-to-human spread happen when humans come into contact 
with tissues and bodily fluids of infected animals, particularly with 
infected nonhuman primates[18]. The natural reservoir for ebola 
has yet to be confirmed; however, bats are being recognized to be 
the most likely species and transmit the virus without getting ill. 
Plants, arthropods and birds have also been regarded as possible 
viral reservoirs[35]. Traces of ZEBOV were found in the carcasses 
of gorillas and chimpanzees during outbreaks in 2001 and 2003, 
which later became the source of human infections. Conversely, the 
high mortality rate in these species causing from ZEBOV infection 
accomplish unlikely; these species are a natural reservoir for the 
virus[36].
   It is pertinent to mention that human-to-human spread of the 
ebola virus is basically accompanied with direct contact with 
the blood or numerous body fluids (saliva, mucus, vomit, feces, 
sweat, tears, breast milk, urine and semen) of a person who has 
developed warning sign of the ailment and indirect contact with 
environment contaminated with infected body fluids. The threat of 
ebola spread increases when there has been an interaction with a 
patient in the later stages of disease[37,38]. In the first ebola outbreak 
in the Democratic Republic of the Congo, in Yambuku, the reuse 
of unsterilized needles and syringes was an imperative factor in the 
transmission of the disease. In the Kikwit outbreak, several clinic 
employees got infected because of improper barrier measures[39,40]. 
The preliminary replication happens in monocytes, macrophage 
and dendritic cells and via these cells distribution of virus occurs to 
lymph nodes, spleen, liver and other organs. An evident increase of 
interleukin-2, interleukin-10, tumour necrosis factor, interferon-alpha 
and gamma were observed in fatal EHF cases. The virus is capable to 
persist on objects for a several hours in a dried state and can persist 
for a few days within body fluids[41,42]. More noteworthy effects 
are microvascular damage, changes in vascular permeability and 
activation of the clotting cascade. The impairment to platelets and 
endothelial cells cause disruption of fluid balance and homeostasis. 
In addition, the virus is considered to deal and hide immunological 
function[43]. The virus has been found in semen for up to 7 weeks after 
recovery from the illness, indicating the probability of sexual mode 
of transmission. Ebola virus infection may also spread through breast 
milk of women after recovery and it is unknown when it is prudent 
to breast feed again. Otherwise, person who recovered are not 
infectious[44]. Aerosol transmission has been put forwarded among 
monkeys infected with the Reston and Zaire subtypes of ebola virus. 
Ebola virus has also been recognized in alveoli of experimentally 
infected monkeys[45]. The spread array during epidemic in humans 
does not advocate respiratory route of transmission. No incidence 
proposes the role of insects in transmission of EVD[46,47]. Dead 
bodies remain infectious; thus, people handling human remains in 
procedure such as traditional burial rituals or more modern processes 
such as embalming are at threat[48](Figure 2). 
Figure 2. Modes of transmission of ebola virus infection[49].
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7. Clinical manifestations
   The harshness of different species has been found to be of variable 
grade. ZEBOV is the most severe with casualty rate approaching 
90%, while Sudan ZEBOV (SEBOV) have 53%-66% mortality 
rate[50,51]. The disease has an incubation period of 2-21 days 
(average 4-10 days) followed by its symptoms like fever followed 
by headache, fatigue, dysphagia or odynophagia, abdominal 
pain, myalgia, sore throat, cough, anorexia, nausea, vomiting and 
diarrhea[44]. A conjunctival infection is often an early clinical sign 
and sometimes patients may also have hiccoughs, tachypnoea and 
bleeding and shock. Dermatological indications include a typical 
maculopapular rash on trunk, but this is more frequently observed 
on white people than darker skin people. Patients may also acquire 
neurological warning signs, namely, convulsions, delirium and 
coma. Patients normally die 6-9 weeks after the first indications 
but differences in death rates have been detected between epidemic 
and during an epidemic. In surviving patients, improvement may 
be gradual and is frequently illustrated by fatigue and arthralgia[45]. 
From these clinical indications, it is clear that EHF may mimic 
several other tropical ailments like malaria, typhoid fever or yellow 
fever at the start of the disease. In most outbreaks, identification of 
the disease is slow because physicians are not familiar to this new 
illness and the symptoms are generally non-specific (Figure 3). 
Figure 3. Early signs and symptoms of ebola virus[49].
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8. Diagnosis
   The diagnosis of EVD is very difficult as it needs a careful, 
complete history as well as a full examination. The acute febrile 
illness is the general appearance in the early part of the disease. In 
endemic countries, various parameters like travel to jungle, eating 
or hunting of bats or animals, contact to cave, close exposure with 
ill persons or dead bodies help in settling the apprehension for ebola 
virus infection. In non-endemic countries, patient with history of 
travel to disease prevalent countries or outbreak affected areas, if 
detecting acute febrile illness, should be assumed for ebola virus 
infection and diagnosed accordingly. The direct detection of the ebola 
virus can be performed using immunofluorescent methods, ELISA, 
immunohistochemistry and PCR. As enormous amount of ebola 
virus are found in dermal tissues, skin biopsies are considered for 
post-mortem confirmation of the ebola infection for investigations. 
Earlier to this serological testing of ebola virus infection was carried 
out using indirect fluorescent antibody method although this test 
has difficulty of unambiguity and sensitivity. An IgM capture ELISA 
assay is further helpful in the detection of acute infections and a 
direct IgG ELISA assay should substitute the indirect fluorescent 
antibody for seroprevalence evaluations[52-57]. In 1995, Dr. Sherif 
Zaki of the CDC established a colorimetric assay for identification of 
ebola virus in formalin-preserved skin biopsies from fatal cases of 
alleged EHF infection. Some supplementary tests, namely, complete 
blood count, metabolic panels, liver enzymes and coagulation 
studies are also helpful in the diagnosis[58-60]. Among the other 
serological tests, western blot and indirect immunofluorescence tests 
can also be employed for verification and examination, respectively. 
Sophisticated diagnostic tests like multiplex PCR and micro-array-
based assay have also been developed on the basis of the common 
clinical disorder[46].
9. Treatment
   There is no precise remedy for EHF. The management of patients 
with ebola virus infection was a main threat as there was no 
successful antiviral drug and no specific vaccine was available. 
The treatment is mainly based on supportive and symptomatic 
remedy focusing on supplying proper hydration and nutritional 
support with antibiotics, control of organ failure, and antimalarial 
drugs if required. Another essential measure includes avoidance of 
disease spread by severe quarantine of infected person and using 
impediment nursing operations. Personal protective instruments and 
surface cleaning, following the safety procedure suggested by CDC 
directions should be employed in the case where risk of infection 
is from dead bodies[61]. In a clinical investigation performed 
late in the 1995 ebola epidemic in Kikwit, blood transfusions of 
improving patients were administered to eight ebola patients for 
passive immunization and seven of them stayed alive[62]. Such type 
of investigations were not repeated in further outbreaks as in vitro 
assay indicated that antibodies against ebola had no neutralising 
action. Furthermore, monoclonal antibodies to the GP of ebola virus 
exhibited defensive and healing properties in mice but they were 
unable to protect NHP[63,64]. The animal studies suggest that ebola 
specific immunoglobulin of equine origin has little activity in hiding 
viraemia and slowing disease onset in NHP. Goat immunoglobulins 
were evaluated in pre-clinical test on laboratory animals and were 
administered to scientist assumed of gaining infection with EHF 
during their investigational work. It was suggested that these 
immunoglobulins might be beneficial for the emergency cure 
of persons inadvertently infected with EHF[65]. The ebola virus 
reproduction was shown to be hindered in vitro by a series of nine 
nucleoside analogue inhibitors of S-adenosylhomocysteine hydrolase 
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and carbocyclic 3-deazaadenosine was shown to avert death in mice 
infected with the ebola virus[66]. Various clinical aids like injections, 
catheters and parenteral interventions etc should be reduced to 
avert trauma and the increased challenge of disease spread. Several 
drugs specially aspirin, nonsteroidal anti-inflammatory drugs, 
anticoagulant therapies, and steroids should be contraindicated[67]. 
   The recommendations of WHO for treatment at home have been 
comparatively effective if specialized care is not available[68]. 
The research work is going on to discover a drug for effective 
cure of patients infected with EVD. Currently, the main classes of 
drugs being evaluated for their potential against ebola infection 
include RNA inhibitor based (TKM-Ebola) agents, monoclonal 
antibodies (ZMapp), nucleoside analogs, positively charged 
phosphorodiamidate morpholino oligomers and antisense-based 
(AVI-7537) drugs. Favipiravir (T-705) a pyrazine carboxamide 
derivative, is another hopeful candidate, acting by prevention of 
viral replication. ZMapp is one of the most encouraging agents act 
by targeting the expression phase of viral replication. It comprises 
of 3 monoclonal antibodies created in tobacco plants. It binds to 
the protein of the ebola virus to inhibit replication of the virus once 
introduced into the host[69]. Another promising drug, BCX4430 
possessing antiviral activity for marburg, ebola and yellow fever is 
also being tested for its capability to target an enzyme found in these 
specific viruses. BCX4430 has been found effective in small animals 
if treatment is initiated within 48 h after infection[70]. The off-label 
usages of angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers and statins have been advised for cure due to their 
ability to encourage immunity in the infected person. Ebola virus is 
normally considered as a conceivable biological weapon, thus there 
is a crucial need to develop effective antiviral drugs and vaccines.
10. Conclusion 
   Ebola virus has been a threat to human health due to dangerous, 
highly lethal and infectious behavior since its discovery in 1976. 
Ebola fever has come out as one of the most fatal identified forms of 
hemorrhagic fever, for which there is no specific remedy available. 
The spread among humans occurs mainly through the exchange of 
blood and body secretions. Other noticeable forms of transmission 
include hospital acquired infection and inadequate hygiene practices. 
There is an urgent requirement of dissemination of information to 
community and training programmes for doctors, nurses and other 
hospital staff.
   The future endeavors require the emphasis on the understanding 
of the differences among species of ebola virus. There is an 
urgent demand for more field studies into the ecology of reservoir 
species and shedding procedures. The discovery of novel targets 
for intervention tactics requires more exhaustive research into the 
pathophysiology of ebola virus infections with laboratory animals. 
The best method to lower the cases and epidemic is to prevent 
the spread of the disease. The awareness programmers should be 
organized on large scale to develop the attentiveness about disease 
for its eradication. The research should also essentially be focused on 
establishment of rapid and simple diagnostic kits for ebola infection. 
It is anticipated that outcome of research investigations would 
result in development of easily available and affordable drug for the 
treatment of ebloa virus. A great effort with clear strategy is needed 
for transforming the potential drugs and vaccines from lab to clinical 
trials and ultimately for treatment of patients with ebola infection. 
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